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In this review, recent key publications related to acute coronary syndrome (ACS) are summarized and placed into context of contemporary practice. Landmark trials examining vascular access in ST-elevation myocardial infarction, the management of multivessel disease, acute myocardial
infarction and cardiac arrest are discussed. An update in pharmacology for ACS provides updates in major trials relating to P2Y12 inhibitor initiation, deescalation, and use in special populations. Additional updates in the use of lipid-lowering agents and adjunctive medications in ACS are
reviewed. Finally, cardiac pathology related to coronavirus disease 2019 (COVID-19), as well as the impact of the COVID-19 global pandemic
on the care of patients with ACS, is summarized.
Ó 2021 Elsevier Inc. All rights reserved.
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DESPITE ADVANCES in the management of heart disease,
cardiovascular disease remains a leading cause of death.
Patients with acute coronary syndrome (ACS) represent one of
the highest risk groups in this cohort. Advances in the diagnosis and management of ACS have shaped the way that these
patients are identified,and treatment strategies have evolved.
In this review,the authors discuss the most impactful publications related to ACS in 2020 and place them in the context of
this evolving field. The year 2020 was also historic as the
global spread of coronavirus disease 2019 (COVID-19) predominated clinical medicine and biomedical research. In this
review,the authors also discuss the impact that the COVID-19
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pandemic has had on the management of patients with ACS as
well as the cardiac manifestations of COVID-19
Epidemiology
The long-term epidemiology of coronary heart disease has
been studied in multiple longitudinal cohort studies. The 50year follow-up of the European Seven Countries Study was
published in 2020.1 This study followed 6,500 men who were
40-to-59 years old at the time of enrollment and illustrated
changes in the prevalence of risk factors over time, notably
demonstrating reductions in smoking and serum cholesterol
levels, as well as increases in average blood pressure. As the
frequency of risk factors decreased over the study period, the
hazard rate for mortality decreased.
Similarly, temporal trends in hospitalizations for acute myocardial infarction (MI) have shown marked reductions over time,
with a large cohort from Kaiser Permanente demonstrating a
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48% reduction in hospitalizations for ST-elevation myocardial
infarction (STEMI) and non-STEMI (NSTEMI) between 2000
and 2014.2 Analysis of acute MI (AMI) hospitalization trends by
race revealed that Caucasian patients had a disproportionate
reduction in hospitalizations for AMI compared with Hispanic
and Black patients during this period. These findings shed light
on persistent racial disparities in cardiovascular disease awareness, treatment, and risk factor optimization. Analysis of the
same cohort demonstrated similar disparities when patients were
stratified by gender, with the rate of reduction in hospitalization
lower among women than men.3 Despite higher rates of primary
prevention, women with AMI are less likely to undergo revascularization and receive treatment for secondary prevention than
men.4 Identification of groups with lagging improvements in outcomes is a key step in achieving equitable healthcare outcomes.
Risk Factors
Further risk factor elucidation in 2020 was notable for new
insights into the role of malnutrition and smoking in ACS. In a
retrospective study in northern Spain, researchers evaluated
the nutritional status of patients discharged with a diagnosis of
ACS.5 Using validated tools to determine nutritional status,
8% of patients were found to have moderate-to-severe malnutrition. While the worst nutrition scores were associated with a
low body mass index, 8% to 36% of malnourished patients had
a body mass index 25 kg/m2 depending on the nutritional
index used. Poor nutritional status was associated with a twofold increase in the risk for all-cause death. These findings
highlighted the importance of identifying and intervening on
this modifiable risk factor.
Smoking tobacco, an important risk factor for ACS, was
examined in a large pooled analysis of primary percutaneous
coronary intervention (PCI) patients. Increased rates of STEMI
among smokers have been well-established. Previous studies
have observed a favorable prognosis after STEMI among
smokers, with the “smoker’s paradox” phenomenon posited to
be related to ischemic preconditioning and perhaps reduced
infarct size among smokers. Redfors et al. analyzed data from
ten randomized controlled trials in which patients underwent
primary PCI for STEMI, and infarct size subsequently was
characterized by cardiac magnetic resonance imaging or Single Photon Emission Computed Tomography (SPECT).6
Smokers were, on average, ten years younger than nonsmokers
at the time of STEMI and, after adjustment for age and other
risk factors, had a higher risk of death or heart failure hospitalization, as well as reinfarction compared with nonsmokers.
These findings suggested that the “smoker’s paradox” is more
likely to be related to the younger age and lower comorbidity
burden at the time of STEMI in smokers rather than any protective effect of tobacco use.
Diagnostics
After the publication of the Fourth Universal Definition of
Myocardial Infarction in 2018, the classification of acute and
chronic myocardial injury has increased among patients with

elevated troponin biomarkers.7 The myocardial injury group
previously has been shown to have increased mortality. Validation studies of the newly published Fourth Universal Definition have shown reclassification rates up to 30% compared
with the classification based on the Third Universal Definition
of MI.8 The majority of reclassified patients were reclassified
to acute or chronic myocardial injury. This group had significantly higher rates of cardiovascular events compared with
nonreclassified patients. Another study of patients aged 50 and
younger compared patients with type-1 MI, type-2 MI, or myocardial injury based on the Fourth Universal Definition.9
Increased mortality in the type-2 MI and myocardial injury
groups was striking, with nearly half of patients withtype-2 MI
and one-third of patients with myocardial injury dying within
ten years.
While the Fourth Universal Definition has improved the
identification of patients at high risk for subsequent cardiovascular events, particularly among those classified as myocardial
injury, significant controversy continues in the application of
these definitions to clinical trials. Multiple large clinical trials
comparing revascularization strategies have used varying definitions of periprocedural MI, including the Third and Fourth
Universal definitions, as well as the Society for Cardiovascular
Angioplasty definition. As periprocedural MI is a commonly
included component of the composite primary endpoint, nuances between the different definitions have large repercussions
on the outcomes of pivotal clinical trials. As investigators learn
more about the clinical significance of periprocedural MI, the
definition and role of this endpoint in clinical trials remain
controversial.10-12
The Fourth Universal Definition also codified the adoption
of hs-troponin assays in the diagnostic algorithms for MI and
myocardial injury. Adoption of hs-troponin resulted in the
increased diagnosis of type-1 MI, type-2 MI, and myocardial
injury by 11%, 22%, and 36%, respectively.13 Despite an
increased number of patients diagnosed with MI and myocardial injury, similar increases were not observed in treatment or
improved outcomes.
An additional application of hs-troponin is the potential role
of this biomarker to rule out MI in patients presenting to the
emergency department with chest pain. An analysis from the
APACE study, an international multicenter study aimed at
early diagnosis of MI, a single hs-troponin C measurement
with a cut-off value of <3 ng/L had a negative predictive value
of 100%, and a cut-off of >60 ng/L had a 77% positive predictive value.14 Application of hs-troponin in the diagnostic algorithm of suspected MI was able to rule out 55% of patients,
with ruled-out patients having an event rate of 0% at 30 days
and 1.6% at two years.
Among patients ruled in for non-ST elevation ACS
(NSTEACS), coronary computed tomography angiogram
(CTA) has become another diagnostic modality under investigation to identify those who would benefit most from invasive
coronary angiography. In the VERDICT trial, patients with
NSTEACS were randomized to very early or standard invasive
coronary angiography.15 Clinically-blinded coronary CTA was
performed in both groups to determine the accuracy of
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coronary CTA in ruling out stenoses <50% compared with
invasive coronary angiography. In this study, the negative predictive value of CTA was 91%, suggesting that among patients
with NSTEACS, coronary CTA may be appropriate to identify
the group of patients who are less likely to derive benefit from
invasive imaging.
Vascular Access and Bleeding
The relationship of bleeding with recurrent thrombotic events
and mortality in patients with ACS has been well-established.
The implications of postdischarge bleeding were further elucidated by Marquis-Gravel et al in a large posthoc analysis of data
from four randomized trials comprising more than 45,000
patients.16 Among patients with noncoronary artery bypass grafting-related Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries moderate, severe, or
life-threatening bleeding landmarked to seven days after presentation, mortality was higher, particularly in the 30 days following
discharge. Increased mortality in association with bleeding was
similar among groups managed medically versus those who
underwent PCI. While the application of these findings to individualized patient care decisions remains nuanced, these findings
provide important insight into post-ACS bleeding among patients
managed medically for ACS.17
The importance of vascular access selection in ACS has been
studied extensively over the last decade. Multiple trials have
examined the role of femoral versus radial arterial access in primary PCI. Previous randomized control trials largely have shown
reduced bleeding and lower mortality in patients with radial access
compared with femoral access in the setting of STEMI.18-20 The
SAFARI-STEMI trial, published in 2020, brings these findings
into question.21 In this open-label randomized trial, nearly 2,300
patients at five Canadian centers were randomized to radial versus
femoral access in primary PCI, with a primary endpoint of 30-day
all-cause mortality. The trial was stopped prematurely due to futility, with no difference in mortality or bleeding observed between
the radial versus femoral groups. The low overall bleeding and
mortality rates reflected a less sick cohort of patients than studied
in previous trials, as well as the adoption of multiple bleeding mitigation strategies, including high rates of bivalirudin use, low rates
of GP IIB/IIIA inhibitors, and high rates of femoral closure device
use. These differences between the SAFARI-STEMI trial and historic studies make it difficult to rule out small differences between
access site groups in contemporary practice. Overall, controversy
remains regarding default femoral or radial access in STEMI.
While this study is unlikely to lead to any significant changes in
guidelines, it is encouraging to see that that with contemporary
pharmacology and bleeding mitigation strategies, mortality and
bleeding can be comparable regardless of access sites among
highly experienced operators.22
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up data were published from the DANAMI-2 trial, which randomized nearly 1,600 patients in Denmark to fibrinolysis versus
primary PCI. Consistent with previously published 30-day and
three-year outcomes, the 16-year follow-up demonstrated a persistent benefit among patients treated with primary PCI compared
with fibrinolytics, with a lower composite primary outcome of
death or rehospitalization for MI, as well as lower cardiac mortality compared with patients treated with fibrinolysis.23 These findings also were seen in the subgroup of patients who required
transfer to a different facility for primary PCI.
Ten-year data examining patient outcomes in STEMI with
primary PCI with bare-metal stents versus everolimus-eluting
stents from the EXAMINATION trial were presented.24
Patients in the everolimus-eluting stent arm had lower rates of
the primary composite endpoint of all-cause mortality, recurrent MI, or revascularization, which was driven by the lower
rates of all-cause mortality (4.4% absolute risk reduction).
Additionally, target lesion revascularization was higher among
patients randomized to bare-metal stents. These long-term
findings are reassuring as they supported the current practice
of near-universal adoption of drug-eluting stents in ACS.
Adjunctive therapies in primary PCI in STEMI have
evolved similarly over time. The role of intracoronary fibrinolytics in STEMI was studied by McCartney et al in an effort to
determine if low-dose alteplase after percutaneous transluminal coronary angioplasty could reduce microvascular obstruction as measured by cardiac magnetic resonance imaging.25
The authors postulated that degrading fibrin-bound thrombotic
debris in the microcirculation could result in reduced microvascular obstruction. Unfortunately, the authors found the
opposite, with increased microvascular obstruction among
patients treated with alteplase in a dose-dependent fashion.
These findings were postulated to be due to hemorrhagic transformation and vascular injury in the setting of ischemia and
were particularly striking among patients with four-to-six
hours of ischemia compared with those with less ischemic
time. These findings continue to reduce the role of intracoronary lytics as the potential for harm is further appreciated.
For the review authors here, a further contribution to the
understanding of the role of PCI in NSTEACS came from
Kaura et al, who examined outcomes in patients aged 80 and
older.26 This group largely has been excluded from prospective
trials examining the role of PCI versus medical therapy in
ACS. In the propensity-matched observational data from the
United Kingdom, researchers found that patients treated with
PCI had markedly lower five-year mortality (hazard ratio [HR]
0.66) and heart failure admissions compared with matched
patients who were medically treated. Despite advanced age,
these patients showed clinically significant improvement in
both quality of life and mortality outcomes. These findings
support the invasive management of NSTEACS in elderly
patients when clinically appropriate.

Reperfusion Strategies
Management of Multivessel Disease
The superiority of primary PCI over fibrinolysis in the acute
management of STEMI was established by a series of key trials
in the late 1990s and early 2000s. This year, the 16-year follow-

Over the last decade, a growing body of evidence has supported the revascularization of nonculprit lesions in the setting
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of STEMI (Fig 1).27-30 The COMPLETE trial, published in
late 2019, randomized more than 4,000 nonshock patients with
multivessel coronary disease presenting with STEMI to complete revascularization versus culprit lesion-only intervention.31 The COMPLETE trial demonstrated that in patients
with STEMI and multivessel disease, complete revascularization was superior to culprit-only PCI, with reduced rates of
death or MI, as well as reduced cardiovascular death, MI, or
ischemia- driven revascularization in the complete revascularization group.
Two meta-analyses of more than 7,000 patients in ten randomized trials of nonculprit PCI in STEMI were published in
2020.32,33 Both analyses demonstrated reduced cardiovascular
mortality and subsequent MI without increased risk of vascular
complications, bleeding, or acute kidney injury in the complete
revascularization groups compared with the culprit-only
groups.
In a subgroup analysis of the COMPLETE trial, severe stenoses, defined as quantitative coronary angiography lesions of
60%, were found to be associated with the coprimary endpoints of the trial.34 The findings that cardiovascular death and
MI were reduced to a greater extent in the group of lesions
meeting criteria for severe stenosis by quantitative coronary
angiography provided insights on the mechanism of recurrent
spontaneous MI after STEMI. While procedural MI predominates the etiology of coronary events in the first 30 days after
PCI for ACS, more than 80% of recurrent ACS beyond
30 days are spontaneous, rather than stent thrombosis or procedure-related MI.35 Controversy has remained regarding which
types of lesions are most likely to be future culprits, with conflicting data as to the importance of mild-to-moderate lesions

versus more severe stenoses. Based on this subgroup analysis,
recurrent spontaneous MI was associated with severe stenosis,
providing some biologic insight as to the mechanism for
reduced cardiovascular mortality and MI observed in the
COMPLETE trial. While caution must be exercised in interpreting subgroup analyses, these conclusions provided insights
as to the direction for future studies.36
Further analyses examining the types of noninfarct-related
lesions most likely to result in spontaneous MI following
STEMI were conducted on data from the COMPARE-ACUTE
trial.37 In this substudy, noninfarction-related arteries were
interrogated by fractional flow reserve (FFR) following successful primary PCI. The investigators were blinded to the
FFR results, and all noninfarction-related lesions were medically treated. In this 24-month natural history study, lesions
with a lower FFR (eg, more physiologically significant lesions)
were more likely to have major adverse cardiac events, MI,
and target vessel revascularization.
Overall, the preponderance of data support the revascularization of noninfarction-related angiographically severe lesions
following STEMI in patients who do not present with cardiogenic shock. Less robust evidence is available for patients
with multivessel coronary disease presenting with NSTEMI. A
retrospective analysis by Kim et al compared three-year outcomes among patients with multivessel coronary disease presenting with NSTEMI who underwent culprit-only, singlestaged, or multistaged complete revascularization.38 The
authors found higher rates of all-cause death, non-fatal MI, or
repeat revascularization among the group of patients who
underwent culprit-only revascularization compared with those
who underwent complete revascularization. No significant

Fig. 1. A summary of contemporary randomized trials of complete revascularization following STEMI, all of which show a benefit with respect to the primary
endpoint in patients undergoing complete revascularization.
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difference was seen between the complete revascularization
groups whether the noninfarction-related lesions were treated
in the index procedure or staged. While retrospective analyses
have significant limitations, these findings are certainly
hypothesis-generating as the role of complete revascularization following ACS is further elucidated.
Acute MI and Cardiac Arrest
Despite advances in the management of acute MI, patients
presenting with MI and out-of-hospital cardiac arrest continue
to have high rates of mortality. Several key publications in
2020 have further defined the role of immediate angiography
in out-of-hospital ventricular fibrillation/ventricular tachycardia (VT/VF) arrest survivors, characterized as patients with
MI most likely to present with cardiac arrest, and identified
optimal treatment strategies for this group (Fig 2).
Immediate coronary angiography and PCI were recommended by both American and European guideline documents
in patients presenting with out-of-hospital cardiac arrest found
to have STEMI following the return of spontaneous
circulation.39,40 In resuscitated cardiac arrest patients with an
initial shockable rhythm who do not have a STEMI on an
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electrocardiogram following resuscitation, coronary angiography historically has been recommended without high-quality
evidence supporting this practice. The COACT trial randomized cardiac arrest survivors presenting with an initial rhythm
of VT/VF and no STEMI on an electrocardiogram to immediate coronary angiography versus delayed coronary angiography following neurologic recovery.41 In 2019, the 90-day
results were published, which showed no difference in survival
or any secondary endpoints between the immediate angiography and the delayed angiography groups. One-year follow-up
of the COACT trial was published in 2020.42 The findings at
one year were consistent with the 90-day outcomes, with no
differences in several key endpoints, including survival, MI,
revascularization,
implantable
cardioverter-defibrillator
shocks, quality of life, and heart failure hospitalization
between the immediate versus delayed angiography groups.
This data suggested that it is safe to defer angiography in this
group of patients until neurologic recovery without any
adverse short- or long-term consequences.
Among patients undergoing urgent PCI for AMI, Kosugi
et al identified the characteristics of patients most likely to
present with out-of-hospital cardiac arrest.43 In this study, the
authors retrospectively analyzed 480 patients at a single center

Fig. 2. Multiple trials in 2020 have further elucidated the optimal care of patients with AMI and cardiac arrest, enhancing the appropriate use of diagnostics, postarrest care, and subsequent risk stratification in this cohort.
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in Japan who underwent PCI for AMI. Patients who underwent
angiography for AMI and presented with out-of-hospital cardiac arrest were compared with patients with AMI not complicated by cardiac arrest. In this selected group of patients,
cardiac arrest survivors had a considerably lower in-hospital
survival compared with those who presented without cardiac
arrest (62% v 96%). The authors found that younger age, no
use of calcium-channel blockers, worse renal function, higher
peak CK-MB, culprit lesion as the left main coronary artery,
and presence of a chronic total occlusion were associated with
AMI presenting with out-of-hospital cardiac arrest. Smaller
infarction size, good renal function, VT/VF as the presenting
rhythm, and no need for extracorporeal membrane oxygenation were predictors of in-hospital survival among those presenting with out-of-hospital cardiac arrest.
Optimal postarrest care continued to evolve in 2020. The ideal
blood pressure goal in postarrest patients with AMI has been controversial; low blood pressure may result in end-organ hypoperfusion leading to worse neurologic outcomes and larger infarction
sizes, while higher blood pressure targets may require higher
doses of pressors and lead to more dangerous atrial and ventricular arrhythmias. A patient-level pooled analysis of two randomized controlled trials in postarrest patients with AMI evaluated
optimal blood pressure targets.44 Patients were randomized to a
lower or higher target blood pressure (mean arterial pressure
[MAP] of 65 mmHg v 80-100 mmHg). Despite higher doses of
inotropes and pressors, the higher MAP group did not have higher
rates of arrhythmias, and the infarction size was smaller. There
was no difference in 180-day survival between the two groups.
While this analysis failed to demonstrate differences in patientcentered outcomes, the lack of increased arrhythmias at higher
doses of pressors provides reassurance that the strategy of higher
MAP targets is safe.
Finally, analyses of the SWEDEHEART registry attempted to
improve identification of patients at the highest risk of cardiac
arrest in the 90 days following hospital discharge for AMI.44 The
authors found that out-of-hospital cardiac arrest was relatively
rare in the 120,000 patients included in the analysis, with a
<0.3% incidence of subsequent cardiac arrest. In an effort to better identify post-MI patients at the highest risk of out-of-hospital
cardiac arrest in the 90 days after discharge, the authors analyzed
clinical variables to stratify risk, creating a risk score incorporating six parameters (male sex, diabetes, poor renal function, Killip
class II or worse heart failure, new-onset atrial fibrillation and/or
flutter, and impaired left ventricular ejection fraction). While this
risk score performed better than depressed left ventricular ejection fraction alone, patients in the highest risk group only had a
2% risk of out-of-hospital cardiac arrest. Further research is
required to identify the post-MI group at the highest risk of outof-hospital cardiac arrest which, while rare, is devastating.
Pharmacology
Antiplatelet Agents
Antiplatelet therapy is a pharmacologic cornerstone of the
management of ACS. In particular, P2Y12 inhibitors have

been the subject of scrutiny as the optimal agent, timing of initiation, and duration of therapy continue to be defined. Several
key studies published in 2020 have helped to further elucidate
the optimal strategies for the initiation and cessation of P2Y12
inhibitors as well as their roles in special populations.
P2Y12 Inhibitor Initiation
Timely P2Y12 inhibitor initiation in STEMI has been recommended by the United States and European guideline documents. Despite emphasis on early P2Y12 inhibitor
administration, data demonstrating improved clinical outcomes with prehospital P2Y12 inhibitor administration is lacking.45 A hypothesized reason for this lack of benefit is the
prolonged time required for gastric transit and absorption. One
method that has been explored to address this barrier is crushing P2Y12 inhibitors prior to administration. Vlachojannis
et al conducted a randomized trial of more than 700 STEMI
patients in the Netherlands investigating the clinical effect of
crushed prasugrel.46 Eligible patients who presented within six
hours of symptom onset and were scheduled for primary PCI
were randomized to a 60-mg loading dose of prasugrel, administered as crushed or integral tablets. The authors were unable
to demonstrate any differences between the two groups with
respect to the coprimary endpoints of TIMI 3 flow in the
infarct-related artery on initial angiography or the resolution
of ST elevation one hour after primary PCI. As the rates of
stent thrombosis and mortality in STEMI have decreased dramatically due to improvements in stent engineering, PCI techniques, and STEMI systems of care, it has become
increasingly difficult to demonstrate significant outcome differences with new agents or strategies in the setting of STEMI.
In this study, the average time from randomization to angiography was just slightly more than 20 minutes. Oral agents,
regardless of the administration method, are unlikely to be
able to demonstrate a significant difference in such a compressed timeframe.
In order to address the delay in onset of action with current
oral agents, the novel P2Y12 inhibitor selatogrel has been
developed. This agent is administered subcutaneously and has
been shown in pharmacodynamic studies to have a rapid onset
of action. In a phase II clinical trial, 47 patients presenting
with AMI were randomized to a single dose of selatogrel, 8 or
16 mg, followed by ticagrelor.47 At 30 minutes, 91% of lowdose and 96% of high-dose patients had effective platelet inhibition that was sustained at 60 minutes. No major side effects
or bleeding complications were noted. These initial findings
are promising as the agent of choice in the preprocedural management of STEMI continues to be emphasized, and the phase
III trial of selatogrel is planned.48
The timing of P2Y12 inhibitor initiation in NSTEMI similarly
has been a historic area of controversy. The largest study questioning routine pretreatment with P2Y12-inhibitor administration
in NSTEACS was the ACCOAST trial, which found that patients
pretreated with prasugrel had no benefit in ischemic endpoints
and had higher rates of serious bleeding.49 The DUBIUS study,
published in 2020, was an open-label randomized controlled trial
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of more than 1,400 patients with NSTEMI. Patients were randomized to ticagrelor administration upstream (pretreatment) versus downstream (at the time of angiography).50 The study was
terminated prematurely due to futility at the interim analysis,
with no differences in the primary composite efficacy and safety
endpoints. These findings, in concert with previously published
work, showed that routine P2Y12 pretreatment in NSTEMI is at
best not helpful and at worst harmful, with increased bleeding
events.51
Following the publication of PLATO and TRITON-TIMI
38, the P2Y12 inhibitor of choice in patients with NSTEACS
has been prasugrel or ticagrelor.52,53 Limited data have supported the choice of one of these agents over the other. Posthoc
analysis of the unstable angina and NSTEMI groups of the
ISAR-REACT 5 trial compared patients randomized to ticagrelor versus prasugrel.54 The authors found prasugrel to be
superior in reducing the one-year composite endpoint of death,
MI, and stroke without increasing the risk of serious bleeding.
This posthoc analysis is hypothesis-generating and was limited
by the initial open-label trial design; however, the findings are
reassuring in that no differences in bleeding were observed
when directly comparing prasugrel and ticagrelor in patients
with NSTEACS.55

Antiplatelet Therapy De-escalation
As the significance of bleeding events has become widely
appreciated, P2Y12 inhibitor deescalation and cessation have
been an area of considerable interest in ongoing clinical trials.
The TWILIGHT trial randomized 9,000 patients who were
identified as highrisk for bleeding or ischemic complications
to dual-antiplatelet therapy (DAPT) with ticagrelor and aspirin
versus ticagrelor monotherapy after successfully completing
three months of DAPT.56 The investigators found a lower risk
of serious bleeding in the ticagrelor monotherapy group, with
no increase in ischemic outcomes. Several subgroup analyses
of the TWILIGHT trial subsequently have been published. In a
prespecified subgroup analysis of patients undergoing complex
PCI as defined by coronary anatomy and extensive and/or
complex stenting techniques, patients in the ticagrelor monotherapy group continued to show benefit compared with those
treated with DAPT despite a theoretically higher risk of stent
thrombosis in more complex stenting.57
In patients presenting with ACS, a subgroup analysis of
patients in the TWILIGHT trial also showed a benefit with
ticagrelor monotherapy over DAPT, with the benefit of
reduced bleeding events more pronounced among patients
with ACS than those with stable ischemic heart disease.58 Similar results were observed in the TICO study that was designed
similarly to TWILIGHT with the exception of limiting enrollment to patients who underwent stenting for ACS.59 After tolerating DAPT with aspirin and ticagrelor for three months,
patients were randomized to ticagrelor monotherapy versus
DAPT for the next nine months. Similar to TWILIGHT, the
authors found reduced composite bleeding, cardiovascular,
and cerebrovascular events in the ticagrelor monotherapy
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group driven by a reduction in major bleeding (HR 0.56 for
major bleeding).
Prasugrel was studied in a similar fashion in the HOSTREDUCE-POLYTECH-ACS trial, which randomized 2,300
patients who underwent stenting for ACS to DAPT with fulldose prasugrel and aspirin versus low-dose prasugrel and aspirin after completing three months of DAPT.60 Consistent with
TWILIGHT and TICO, patients who were treated with lowdose prasugrel and aspirin had lower net adverse clinical
events at one year, driven by a reduction in the risk of bleeding. Overall, the available data support early deescalation of
P2Y12 inhibitor intensity, particularly among patients at a
high risk for bleeding complications.
Special Populations
Special consideration for the P2Y12 inhibitor use in the
elderly must take into account unique risk factors in this age
group, including increased risk of bleeding, risk of ischemic
events, and cotreatment with anticoagulation. Analysis from
the SWEDEHEART registry compared patients aged 80 or
older who were prescribed DAPT with clopidogrel versus ticagrelor at hospital discharge for a diagnosis of MI.61 After
inverse probability weighting of Cox regression models to
adjust for differences in patient and therapy characteristics, the
authors found no difference in ischemic outcomes with clopidogrel versus ticagrelor. Ticagrelor use was associated with a
significantly higher risk of death and bleeding.
This hypothesis put forth by the registry data was tested in
the POPular AGE trial, which randomized 1,000 patients older
than 70 presenting with NSTEACS to loading and maintenance doses of clopidogrel versus ticagrelor for one year of
treatment.62 Several key findings are notable from this trial.
Premature cessation of ticagrelor was very common, with 47%
patients in the ticagrelor group stopping treatment due to
bleeding or shortness of breath. Bleeding also was frequent in
all subjects but was significantly more common in the ticagrelor group, with 24% of patients experiencing PLATO major or
minor bleeding compared with 18% in the clopidogrel group.
The composite clinical benefit outcome was noninferior for
clopidogrel versus ticagrelor. Overall, this study highlighted
the high frequency of bleeding in elderly patients treated with
P2Y12 inhibitors and demonstrated reduced bleeding with
similar ischemic endpoints with clopidogrel versus more
potent P2Y12 inhibitors.
An additional group that merits special consideration are
those with known cytochrome p-450 polymorphisms that confer reduced clopidogrel metabolism. Patients with loss of function mutations of the CYP2C19 gene have reduced
concentrations of the active metabolites of clopidogrel,
increased platelet reactivity, and an increased risk of subsequent ischemic events.63 Despite these findings, evidence of
improved clinical outcomes when antiplatelet therapy is tailored to individual genetics is lacking.64 The findings of the
TAILOR-PCI randomized trial were consistent with the lack
of benefit in gene-tailored antiplatelet therapy seen in previous
studies. In this trial, 5,300 patients who underwent PCI were
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randomized to standard therapy with clopidogrel versus genotype-guided therapy with ticagrelor substituted for clopidogrel
in patients with CYP2C19 loss of function mutations.65 There
were no differences in composite efficacy or bleeding endpoints in the standard versus genotype-guided therapy groups.
These findings underlined previous work that has shown that
while genotyping can identify higher risk individuals, no effective interventions have been identified to ameliorate this risk.

Lipid-Lowering Agents
The role of lipids in atherogenesis is foundational in the
pathogenesis of coronary artery disease. Identifying and targeting lipid metabolites have further elucidated the mechanistic
role of lipid-lowering therapies. The importance of very-lowdensity lipoproteins (VLDL) was demonstrated in analysis
from the Copenhagen General Population Study.66 This observational study found that elevated VLDL cholesterol explained
half of the MI risk from elevated apoB-containing lipoproteins,
whereas VLDL triglycerides did not account for risk. This was
theorized to be due to an increased direct uptake of VLDL into
macrophages, which then morphologically become foam cells,
a key component of atherosclerotic lesions. These findings
guided future directions for study to reduce MI risk by identifying novel lipid targets.
The most recent major advance in anti-lipid therapy has
been the development and approval of evolocumab and alirocumab, monoclonal PCSK-9 inhibitors. In the landmark
FOURIER and ODYSSEY trials, these agents were shown to
significantly reduce low density lipoprotein (LDL) levels and
adverse cardiovascular outcomes.67,68 A prespecified analysis
from the ODYSSEY trial evaluated the effect of alirocumabinduced changes in lipoprotein A (Lp(a)) and LDL-C on major
adverse cardiovascular events.69 The authors found that both
baseline levels and relative reductions of Lp(a) and LDL-C
were associated independently with a reduction in major
adverse cardiovascular events. While providing mechanistic
insight into the effect of alirocumab, these findings suggested
that Lp(a) may have additional value as an independent treatment target after ACS.
The role of plaque burden and composition in ACS has continued to guide future directions for research. In a large CTA dataset, investigators found that after stratifying patients by calcified
plaque burden, the degree of stenosis did not predict future cardiovascular events.70 That is to say, patients with a similar
amount of plaque had a similar risk for subsequent MI whether
the plaque was diffuse; eg, non-obstructive versus focal; eg,
obstructive. These findings suggested that plaque burden rather
than the degree of stenosis may predict future risk.
Intracoronary imaging has furthered the study of plaque burden and characteristics in vivo. Using near-infrared spectroscopy intravascular imaging, investigators in an international
prospective cohort study imaged nonculprit segments in 1,500
patients undergoing cardiac catheterization for suspected coronary artery disease.71 Investigators were able to demonstrate
the association of large lipid-rich plaques with major cardiac

events over the next two years at both a patient and plaque
level.
The concept that high-risk plaques can be identified and prophylactically treated before progressing to ACS was explored
in the PROSPECT ABSORB study.72 In this pilot trial,
patients who underwent successful PCI for STEMI or
NSTEACS underwent three-vessel intravascular imaging with
intravascular ultrasound and near-infrared spectroscopy. Of
the 902 patients enrolled, 182 had lesions eligible for randomization. Lesions that were <70% stenosed with 65% plaque
burden were randomized to treatment with Absorb bioresorbable vascular scaffold and guideline-directed medical therapy
versus medical therapy alone. The investigators found that PCI
of angiographically mild lesions with large plaque burdens
was safe and associated with a larger minimal lumen area on
follow-up angiography. There were similar rates of target
lesion failure at 24 months. While underpowered to detect any
differences in long-term clinical outcomes, this trial provided
reassuring safety data in preparation for a larger pivotal trial.
Further study and refinement of identification of the highest
risk plaques, as well as robust outcome and safety data, are
required before the adoption of PCI with bioresorbable vascular scaffold is adopted.73
Miscellaneous Medications
Intravenous (IV) morphine historically has been recommended to control pain in patients with ACS despite the
absence of safety data. Given the negative effects of opioids
on gastrointestinal motility, IV morphine prior to PCI in the
setting of ACS has been theorized to delay the absorption of
P2Y12 inhibitors that rely on gastric motility for transit to the
intestine where absorption occurs. Delayed absorption with
lower circulating concentrations of P2Y12 inhibitors and their
metabolites in the time period immediately surrounding PCI
has been theorized to increase thrombotic events and lead to
higher mortality in patients receiving IV morphine prior to
PCI. Previous data in this area have been conflicting, with
some studies showing an impact on all-cause mortality and
composite endpoints and other studies failing to show any difference in outcomes in those receiving IV morphine versus
those who do not.74,75
A posthoc analysis from the EARLY ACS trial examined a
group of patients pretreated with clopidogrel prior to coronary
angiography for NSTEACS and compared the group who
received IV morphine to those who did not.76 After propensity
matching, the group treated with morphine had a higher rate of
the composite endpoints of death, MI, recurrent ischemia
requiring urgent revascularization, or thrombotic bailout at
96 hours (odds ratio 1.40). Periprocedural MI also was
increased significantly in the morphine group, suggesting that
stent thrombosis and thrombotic complications may be driving
these findings. These findings demonstrated the evolving role
of opioids in patients with ACS, particularly among patients
pretreated with clopidogrel, as pharmacologic studies have
shown both delay in absorption, as well as reduced levels of
clopidogrel and its metabolites when coadministered with IV
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morphine. In patients receiving clopidogrel and IV opioids
prior to PCI, intensive antiplatelet therapy with IV cangrelor,
an IV GP IIB/IIIA inhibitor, or a reloading dose in six hours
can be considered to reduce the risk of acute thrombotic
events.77
Following MI, the use of nonsteroidal antiinflammatory
drug (NSAID) medications has been shown to be associated
with increased rates of cardiovascular events and bleeding.
Despite recommendations to avoid NSAIDs in patients with a
history of ischemic heart disease, rates of exposures to
NSAIDs remain high due to the presence of other comorbidities.78 In a nationwide cohort study from Korea with data
from more than 100,000 patients who were diagnosed with
their first MI, NSAID use was associated significantly with
cardiovascular events (HR 9.96) and bleeding events (HR
4.08).79 Among the NSAIDs prescribed, celecoxib and meloxicam had the lowest adjusted rates of cardiovascular events and
bleeding, suggesting that these agents may be the NSAIDs of
choice in patients with a history of MI in whom NSAIDs cannot be avoided.
Inflammation has been known to play an important role in
the pathophysiology of ACS. After the pivotal CANTOS trial,
which demonstrated improved cardiovascular outcomes after
treatment with an anti-inflammatory agent, interest has grown
in the use of other immunomodulating agents in patients with
coronary artery disease.80 Multiple key publications in 2020
investigated colchicine for secondary prevention in this group.
The LoDoCo2 trial randomized patients with angiographic or
computed tomography evidence of coronary disease to colchicine versus placebo.81 In this group of stable patients who had
no clinical events in the six months leading to enrollment, colchicine was associated with a reduction in the composite endpoints of cardiovascular death, spontaneous MI, ischemic
stroke, or ischemia-driven revascularization (HR 0.69).
These results were concordant with the previously published
COLCOT trial, which randomized nearly 5,000 patients with
recent MI to colchicine versus placebo.82 In COLCOT, treatment with low-dose colchicine was associated similarly with
lower composite risks of cardiovascular death, cardiac arrest,
MI, stroke, or urgent coronary revascularization at two years.
A subsequent analysis of time to treatment with colchicine in
the COLCOT trial demonstrated that the benefit of colchicine
was greatest in those who started treatment with colchicine
within three days of MI (HR of 0.52) compared with those
who started treatment more than eight days after revascularization (HR 0.82).83
These positive findings were tempered with contradictory
data from a smaller multicenter randomized controlled trial
from Australia (the Australian COPS trial).84 In a design similar to COLCOT, investigators randomized patients who presented with ACS with angiography showing coronary artery
disease to one year of colchicine versus placebo prior to hospital discharge. No difference was found with respect to the primary composite endpoint and, concerningly, a higher rate of
noncardiovascular mortality was observed in the colchicine
group. Several important limitations are notable, including the
premature cessation of the trial prior to enrolling the target
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number of subjects due to slow enrollment, as well as a significant number of patients lost to follow-up. Despite concerns
regarding statistical power and generalizability of this study,
the findings limited enthusiasm for the wide uptake of colchicine in the post-MI population as further safety data are
awaited.
Some exploratory studies have examined the role of colchicine at the time of PCI. The COLCHICINE-PCI randomized
trial was a single-site trial, which randomized patients undergoing PCI to a one-time oral dose of colchicine versus placebo
at the time of PCI.85 Patients were followed for 30-day composite endpoints of death, MI, and target-vessel revascularization, periprocedural MI, and inflammatory biomarkers.
Despite attenuation in IL-6 and hs-CRP concentrations at
24 hours after PCI, no differences were seen in clinical endpoints. Pre- and periprocedural use of colchicine remains an
ongoing question which is a subject of ongoing research.
COVID-19
Medicine in 2020 was shaped largely by the COVID-19
global pandemic. Much of what is known about COVID-19
was first described and reported in the medical literature in
2020 (Fig 3). COVID-19 infection is the result of the severe
acute respiratory syndrome-related coronavirus 2 virus infecting cells by binding to the human angiotensin-converting
enzyme-2 receptor with the viral surface spike protein.86
While respiratory pathology dominates the clinical presentation of COVID-19, a range of cardiovascular manifestations
have been described, particularly in patients with preexisting
cardiovascular conditions.86,87 Cardiac manifestations of
COVID-19 are varied and are theorized to be related to the
adrenergic drive, systemic inflammatory sequelae, and the
direct infection of myocardial and endothelial cells.88
The association of COVID-19 with myocardial injury and
structural abnormalities was studied in a large multinational
study.89 In this study, investigators compared the in-hospital
morality of COVID-19 patients with myocardial injury who
were found to have structural abnormalities on echocardiography, such as regional wall motion abnormalities, LV systolic
or diastolic dysfunction, Right Ventricle (RV) dysfunction, or
pericardial effusions, to those with structurally normal hearts.
In this cohort of 305 patients, 62% of COVID-19 patients were
found to have myocardial injury demonstrated by elevated cardiac biomarkers. Of those with myocardial injury, two in three
had evidence of structural abnormalities on imaging, the most
common of which was right ventricular dysfunction. A worse
prognosis was observed in those with structural abnormalities
on echocardiography, who had a 32% in hospital mortality
compared with a 19% mortality in patients with biochemical
evidence of myocardial injury with no significant structural
abnormalities.
Another characteristic of COVID-19 is the high prevalence
of thrombotic complications. In a single-center study in the
United Kingdom, patients with COVID-19 who presented with
STEMI were found to have a higher thrombus burden than
those with STEMI in the absence of COVID-19.90 This
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Fig. 3. The SARS-CoV-2 virus has had multiple effects on the cardiac health of patients, both directly through viral-mediated cardiac disease, as well as indirectly
with disruption of systems of care. SARS-CoV-2, severe acute respiratory syndrome-related coronavirus.

observational study noted that patients with COVID-19 and
STEMI showed higher risk of thrombotic complications,
including stent thrombosis, high thrombus grade, and larger
areas of myocardial damage, with a greater degree of left ventricular systolic dysfunction.90 While the pathophysiology of
the pro-thrombotic state of COVID-19 is not completely
understood, COVID-19 has been associated with higher rates
of prehospital cardiac arrest, intensive care admission, and inhospital mortality in patients with STEMI.90
In addition to the direct effect of COVID-19 on cardiac pathology, important secondary effects due to stressors on healthcare
systems adversely affected the care of patients with ACS. Data
collected from studies around the world showed a significant
decline in the number of patients admitted to hospitals due to
ACS in the spring of 2020.91 This phenomenon was attributed to
messaging encouraging the public to remain at home in the early
stages of the pandemic, as well as public fear of contracting the
virus at medical facilities and hospitals. Global reductions in
ACS hospitalizations was observed.92-95 Delayed presentations
and reduced admissions for PCI resulted in increased out-of-hospital deaths, worse outcomes with primary PCI, and increases in
mechanical complications of MI.86-88,91,96
Italy was one of the first countries to have the healthcare
system overwhelmed by COVID-19. Italian hospitals reported
a 48% overall reduction in admissions for ACS during the
spring of 2020, with a 65% reduction in NSTEMI and 27%
reduction in STEMI admissions.97 STEMI outcomes also

suffered, with time from first medical contact to PCI increased
32% and case fatality rates of 17% compared with a historic
control of 10%. Similar trends with a 40% reduction in admissions for ACS were seen in Australia, the UK, and the United
States.93,95,98
Understanding the pathophysiology, management, and treatment of COVID-19 patients with ACS has been the result of
global efforts. Primary PCI remains the standard of care in
STEMI regardless of COVID-19 status. Similar management
strategies are applied to early invasive management versus medical management of NSTEACS.99 While much of the cardiac
effects of COVID-19 remain to be learned, considerable progress
has been made in identifying cardiac manifestations of COVID19, as well as optimizing existing systems of care to provide
effective care for cardiac patients during the global pandemic.
Conclusion
In the last year, there was considerable advancement in the
care of patients with ACS. Particular emphasis on the management of multivessel disease, as well as advances in pharmacology, continue to shift the field to safer, more selective use of
therapies to improve both short- and long-term outcomes. The
COVID-19 pandemic resulted in major disruptions to clinical
care in the spring of 2020. Despite these challenges, lessons
learned and the application of clinical science continue to drive
this evolving field forward.
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